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Abstract 
Introduction: gastric cancer is one of the most common cancer-related causes of death. This is 
mainly due to the lack of good noninvasive method/biomarkers suitable for early-tumour diagnosis and 
planning of further therapy modalities. chemokines play an important role in cancer progression and 
metastasis formation. in gastric cancer patients, clinical relevance of cXcl12 and ccl5 level has 
been postulated.
Aim of the study: efforts were undertaken to examine whether expanded chemokine range may be 
relevant for evaluation of preoperative staging of gastric cancer patients.
Material and methods: Plasma from 66 gastric cancer patients and 11 healthy controls was ob-
tained, and ccl2, ccl3, ccl4, ccl5, cXcl8, cXcl9, and cXcl10 levels were determined by flow 
cytometry Flexset system.
Results: in gastric cancer patients’ plasma an increased level of ccl2, ccl4, ccl5, cXcl8, 
cXcl9, and cXcl10 was observed. in the case of ccl2, cXcl9, and cXcl10, the chemokine levels 
correlated with advanced (iii and iV in TNm classification) disease stage. in the case of ccl4, ccl5, 
and cXcl8, elevated levels were observed in all cancer patients in comparison to healthy donors. 
Conclusions: The accuracy of preoperative diagnosis in gastric cancer may include the monitoring 
of a wide range of chemokines in patients’ plasma. increased levels of chemokines may warn that the 
disease is more advanced than conventional diagnostic procedures suggest.
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Introduction
Chemokines are a family of small (8-14kDa) cytokines 
that induce migration of various cell types [1, 2]. They 
mediate the biological effect on target cells through widely 
distributed G-protein-coupled receptors, which are struc-
turally characterised by seven transmembrane spanning 
domains. Chemokines regulate infiltration of leukocytes 
to the sites of inflammation, injury, or tumour bed [1, 2]. 
The availability of chemokines in the site of inflammation 
is regulated at the level of their biosynthesis, by proteolyt-
ic processing, and by mobilisation of the chemokines by 
cell surface molecules. Chemokines are produced by many 
cell types in the tumour microenvironment including leu-
kocytes, endothelial cells, fibroblasts, epithelial cells, and 
cancer cells themselves [3]. In the tumour bed, chemokines 
from CXCL (CXCL1, 2, 3, 6, 8, 12) and CCL (CCL2, 5, 
7) families were previously detected [4, 6]. As a conse-
quence, chemokines are also present in cancer patients’ 
blood.
The biological role of chemokines in tumour progres-
sion is important because they promote tumourigenesis and 
metastasis formation [2]. Chemokines are responsible for 
modulation of tumour growth by regulation of angiogen-
esis (e.g. secretion of metalloproteinases [MMP] [4-6]), 
tumour-specific immune response (e.g. polarisation of tu-
mour-associated macrophages (TAMs) [2, 4]), and stim-
ulation of tumour cell proliferation [7] in an autocrine or 
paracrine fashion [8]. 
Gastric cancer is the fourth most common cancer 
worldwide and one of the major health problem [9]. Sur-
gical resection is still a primary treatment option, although 
overall survival outcomes remain unsatisfactory. Numer-
ous studies were undertaken to find specific “markers” of 
gastric cancer progression to improve diagnostic proce-
dure. The most promising data suggests that the production 
of SDF-1α in the primary cancer may be such a prognostic 
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factor [10]. High CXCR4/high SDF-1α (CXCL12) expres-
sion in tumour cells is significantly associated with depth 
of cancer invasion, lymph node involvement, and more 
advanced stage of disease [10]. Also, elevated level of 
RANTES (CCL5) in serum of gastric cancer patients cor-
relates with poor prognosis [11]. CCL5 is also a candidate 
biomarker because its measurement is a noninvasive meth-
od useful for diagnosis of gastric adenocarcinoma [12].
Aim of the study
The aim of the study was to determine if other chemo-
kines, namely MCP-1 (CCL2), MIP-1α (CCL3), MIP-
1β (CCL4), IL-8 (CXCL8), MIG (CXCL9), and IP-10 
(CXCL10), are present in the plasma of gastric cancer 
patients (stage I-IV TNM), and if they might be useful as 
serum/plasma biomarkers to improve accuracy of preop-
erative staging. 
Material and methods
Patients and healthy donors
Sixty-six consecutive patients (median age 66 years, 
range 40-76 years) with biopsy-proven gastric cancer at 
different clinical stages were studied (Table 1). All patients 
underwent a surgical treatment, and the pathological stag-
ing was completed according to UICC TNM 7th edition 
classification. In all patients with the fourth-stage palliative 
resection was performed. None of the patients received 
preoperative chemotherapy or chemoradiotherapy. No 
concomitant active inflammatory diseases were diagnosed. 
There were no statistically significant differences between 
patients in stages I+II vs. III+IV regarding age, sex, and 
tumour type according to the Lauren classification.
The control group consisted of 11 healthy donors (me-
dian age 41 years, range 33-61 years). All study partici-
pants signed an informed consent form, and the Bioethical 
Committee of the Jagiellonian University Medical College 
(KBET/491/B/2003) approved the study protocol.
Determination of chemokine levels
Plasma from gastric cancer patients was collected pre-
operatively, and the concentrations of chemokines CCL2, 
CCL3, CCL4, CCL5, CXCL8, CXCL9, and CXCL10 were 
measured simultaneously using a Flex Set bead array (BD 
Biosciences, Immunocytometry Systems, San Jose, CA) 
followed by flow cytometric analysis (FACSCanto, BD 
Biosciences), as described previously [13]. The Flex Set 
beads were discriminated in FL-4 and FL-5 fluorescence 
channels, while the concentration of specified chemokine 
was determined by the intensity of FL-2 fluorescence. The 
amount of chemokines was computed by using the respec-
tive standard reference curve and FCAP Array software 
(BD Biosciences). For all chemokines the detection level 
was 10 pg/ml. 
Statistical analysis
Statistical analysis was performed by nonparametric 
Mann-Whitney test. Differences were considered signifi-
cant at p-values < 0.05.
Results
By the use of bead array assay we detected significant-
ly elevated levels of specified chemokines (CCL2, CCL4, 
CCL5, CXCL8, CXCL9, and CXCL10; Fig. 1A-F) in the 
plasma of gastric cancer patients, compared to healthy donors. 
In our study, the levels of CCL2, CXCL9, and CCL10 
correlated with clinical stage of disease, being highest in 
more advanced cancer patients (III and IV stage in TNM 
classification Fig. 1A, E, F). The levels of CCL4 and 
CCL5 were markedly elevated in the patients’ plasma de-
spite their clinical stage (Fig. 1B, C). The level of CXCL8 
was significantly elevated in the plasma of patients with 
II-IV disease stage (Fig. 1D). The level of CCL2 was ele-
vated only in plasma of patients at stage IV (Fig. 1A). In 
case of CCL3, its level was very low and we did not detect 
any differences between patients and healthy donors (data 
not shown). Chemokine levels did not correlate with histo-
logical type of cancer, but with the TNM stage.
Discussion
The presented study shows that the level of several 
chemokines in the plasma of gastric cancer patients is el-
evated when compared to healthy donors. The differences 
in chemokine levels are related to cancer staging (TNM 
classification) rather than histological type of tumour (no 
differences between LI and LII in Lauren classification, 
data not shown). The elevated level was detected, not only 
in relation to well documented CCL5 and CXCL12 [11, 
14, 15], but also to other chemokines from CC (CCL2, 
CCL4) and CXC (CXCL8, CXCL9, CXCL10) families. 
In our study we observed an increase of CCL5 in plas-
ma of gastric cancer patients, despite their clinical stage. 
Elevated levels of CCL5 were previously described by 
other authors [11, 12]. This was also the case in patients 
Table 1. Patients’ characteristics
Age 66 (40-76) ± 9.8
Sex K – 25 / M –  41
Stage I/II/III/IV I –  11, II –  11, III –  22, IV –  22
Lauren I/II/III I –  30 / II – 32 / III –  4
Total gastrectomy 56
Subtotal gastrectomy 10
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with breast cancer [16], where levels of CCL5 and CCL2 
correlated with tumour progression [16]. In our study, 
CCL2 levels were increased, particularly in plasma of pa-
tients at stage IV. This corroborates with data published 
by Jianghong et al. [17] indicating that CCL2 may have 
a predictive value in such a group of patients. CCL2 has 
proangiogenic activity, and this activity results from mac-
rophage recruitment and activation [18].
Increased levels of CCL3 in the plasma of gastric can-
cer patients was described for the first time by Rajkumar et 
al. as being involved in gastric cancer tumorigenesis [20]. 
However, in our data the CCL3 level was low and we did 
not observe differences between healthy donors and cancer 
patients. The discrepancies may result from the heteroge-
neity of the  Rajkumar study group reflected in the wide 
range of CCL3 concentrations. 
Fig. 1. The concentration of chemokines: A) CCL2, B) CCL4, C) CCL5, D) CXCL8, E) CXCL9, F) CXCL10) in plasma 
from gastric cancer patients (stages are labelled below) and healthy donors (control) determined by FlexSet method. Data 
are presented as mean ± SD
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CCL4 was previously detected in gastric tumour cell 
cytoplasm (intracellular form). Its expression seems to 
be dependent on the tumour type (higher expression in 
non-solid type of poorly differentiated carcinoma) [19]. 
Herein we have shown that CCL4 is present in the plasma 
of gastric cancer patients, and its level is significantly ele-
vated compared to healthy donors. This is in line with the 
data published by Rajkumar et al. [20]. 
Gastric cancer cells may produce CXCL8 both in vi-
tro and in vivo [5, 21]. We observed elevated levels of 
CXCL8 in the plasma of all gastric cancer patients, which 
correlated with the progression of the disease. CXCL8 
was previously identified as a strong angiogenic factor in 
lung, ovarian, prostate, and gastric cancer [22]. CXCL8 
may also facilitate tumour growth by inducing chemotaxis 
of neutrophilic granulocytes, which may further promote 
angiogenesis, tumour growth, and metastasis formation by 
releasing metalloproteases (MMPs) and vascular endothe-
lial growth factor (VEGF) [23]. 
The production of CXCL9, CXCL10, and CXCL11 is 
induced by other cytokines, including members of the in-
terleukin family and interferons. These chemokines inhibit 
angiogenesis in colon carcinoma, melanoma, and uterine 
cervical cancers and are considered as angiostatic chemo-
kines [22]. High levels of CXCL9 and CXCL10 were 
detected previously by immunohistochemistry in lympho-
cyte-rich gastric cancers, characterised by increased levels 
of lymphatic invasion and unfavourable prognosis [24]. 
CXCL10 and CXCL9 were expressed by peritumorous 
macrophages, which attract T cells [25]. Interestingly, 
plasma levels of CXCL9 and CXCL10 decreased signifi-
cantly in gastric cancer patients after surgery [20]. 
In summary, the current state of knowledge leads to the 
conclusion that increased levels of chemokines in plasma 
may help tumour cells to migrate and invade.  In this report 
we are trying to draw attention to a broad range of chemo-
kines, the levels of which are simultaneously elevated in 
gastric cancer patients and, in consequence, may serve as 
adequate indicators of disease stage. Preoperative testing 
of chemokine levels may help to predict the advance of tu-
mours, including the “biological” potential, which reflects 
the TNM classification. 
This study was supported by the state committee for 
scientific research (2 Po5a 049 29).
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